Drug intelligence / Profile preview

Albelin

Development stage
Unknown
Lead developer
Alben Health Care Industries
Modality
Small Molecules
Administration
Oral
01

Overview

Albelin is a combination oral cough syrup developed and manufactured by Alben Health Care Industries. It is primarily indicated for the relief of cough associated with bronchospasm and thick mucus, common in conditions such as bronchitis, bronchial asthma, and chronic obstructive pulmonary disease (COPD). The formulation contains four active components: **ambroxol**, a mucolytic agent that reduces the viscosity of respiratory secretions; **terbutaline**, a selective beta-2 adrenergic agonist that acts as a bronchodilator to relax airway smooth muscle; **guaifenesin**, an expectorant that increases the volume and reduces the stickiness of airway secretions to facilitate their removal; and **menthol**, which provides a cooling sensation and mild local anesthetic effect to soothe throat irritation. This multi-ingredient approach effectively addresses both airway constriction and the accumulation of viscous mucus, improving respiratory comfort and clearance.

Brand names
Albelin
Other names
Albelin Syrup
02

Targets

SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)TRPM8 (Transient receptor potential cation channel subfamily M member 8)ADRB2 (β2)

Beyond the preview

Go deeper on Albelin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Albelin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call